Cetuximab + mFOLFOX6

DRUG2 trials

Sponsors

Sun Yat-sen University, Verastem, Inc.

Conditions

Colorectal CancerMetastatic Colorectal Cancer

Phase 2

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

RecruitingNCT05959356

Sun Yat-sen UniversityMetastatic Colorectal Cancer

Start: 2023-11-09End: 2028-12-31Target: 198Updated: 2025-12-17

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

RecruitingNCT07659795

Verastem, Inc.Colorectal Cancer

Start: 2026-07-01End: 2028-12-01Target: 150Updated: 2026-07-17